---
document_datetime: 2025-12-02 05:34:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/bylvay.html
document_name: bylvay.html
version: success
processing_time: 0.132692
conversion_datetime: 2025-12-28 18:27:15.167175
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Bylvay

[RSS](/en/individual-human-medicine.xml/67447)

##### Authorised

This medicine is authorised for use in the European Union

odevixibat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Bylvay](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76681)
- [More information on Bylvay](#more-information-on-bylvay-65482)
- [More information on Bylvay](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Bylvay is a medicine for treating patients from the age of 6 months with progressive familial intrahepatic cholestasis (PFIC), a rare type of liver disease in which bile acids build up in the liver. Bile acids are a component of bile, a fluid produced in the liver that helps to absorb fats from the gut.

Bylvay contains the active substance odevixibat.

Expand section

Collapse section

## How is Bylvay used?

Bylvay is available as capsules. The recommended dose is 40 micrograms per kilogram body weight. The capsules should be taken once a day in the morning. They can be taken whole or they can be opened and sprinkled on food. If the medicine is not working well enough after three months, the treating physician may increase the dose up to 120 microgram per kilogram body weight.

The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the management of PFIC. For more information about using Bylvay, see the package leaflet or contact your doctor or pharmacist.

## How does Bylvay work?

The active substance in Bylvay, odevixibat, blocks the actions of a protein in the intestine (known as IBAT) that transports bile acid from the intestines into the liver. By blocking the actions of IBAT, odevixibat reduces the amount of bile acid that is transported from the intestines into the liver. This will prevent the build-up of bile acids and damage to the liver tissue.

## What benefits of Bylvay have been shown in studies?

Bylvay was more effective than a placebo (dummy treatment) at reducing the severity of PFIC in one main study, which involved 62 patients aged between 6 months and 18 years. The main measure of effectiveness was based on the number of patients whose bile acid level in the blood decreased by at least 70% after 24 weeks of treatment.

Bylvay treatment led to the required reduction in around 44% (10 out of 23) of patients who received the standard dose (40 micrograms per kilogram body weight per day) and in around 21% (4 out of 19) of patients who received the maximum daily dose (120 micrograms per kilogram body weight per day), compared with 0% (0 out of 20) of those receiving placebo. The study also showed that Bylvay can improve symptoms such as itching and prevent delayed growth.

## What are the risks associated with Bylvay?

The most common side effects with Bylvay (which may affect up to 1 in 10 people) are soft stools, diarrhoea, belly pain, and an enlarged liver. For the full list of side effects of Bylvay, see the package leaflet.

## Why is Bylvay authorised in the EU?

One main study has shown that Bylvay is effective at reducing the amount of bile acid in the blood of patients with PFIC. Bylvay was also effective at reducing signs and symptoms of PFIC such as itching. Because PFIC is a very rare disease, the study was small but the short-term data available indicated that Bylvay could delay disease progression and the need for surgery and/or liver transplantation. The side effects seen to date are considered manageable. Given the seriousness of the condition and the lack of existing treatments, the European Medicines Agency decided that Bylvay's benefits are greater than its risk and it can be authorised for use in the EU.

Bylvay has been authorised under 'exceptional circumstances'. This means that, because the indication is encountered so rarely, it has not been possible to obtain full information about the medicine. Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.

## What information is still awaited for Bylvay?

Since Bylvay has been authorised under exceptional circumstances, the company that markets Bylvay will conduct a study to provide data on the long-term effectiveness of Bylvay. The study will also focus on whether Bylvay treatment delays liver-related surgery and/or liver transplantation for PFIC patients.

## What measures are being taken to ensure the safe and effective use of Bylvay?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bylvay have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Bylvay are continuously monitored. Suspected side effects reported with Bylvay are carefully evaluated and any necessary action taken to protect patients.

## Other information about Bylvay

Bylvay received a marketing authorisation valid throughout the EU on 16 July 2021.

Bylvay : EPAR - Medicine overview

Reference Number: EMA/295840/2021

English (EN) (110.54 KB - PDF)

**First published:** 28/07/2021

[View](/en/documents/overview/bylvay-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-524)

български (BG) (134.55 KB - PDF)

**First published:**

28/07/2021

[View](/bg/documents/overview/bylvay-epar-medicine-overview_bg.pdf)

español (ES) (111.27 KB - PDF)

**First published:**

28/07/2021

[View](/es/documents/overview/bylvay-epar-medicine-overview_es.pdf)

čeština (CS) (133.86 KB - PDF)

**First published:**

28/07/2021

[View](/cs/documents/overview/bylvay-epar-medicine-overview_cs.pdf)

dansk (DA) (109.93 KB - PDF)

**First published:**

28/07/2021

[View](/da/documents/overview/bylvay-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.31 KB - PDF)

**First published:**

28/07/2021

[View](/de/documents/overview/bylvay-epar-medicine-overview_de.pdf)

eesti keel (ET) (99.2 KB - PDF)

**First published:**

28/07/2021

[View](/et/documents/overview/bylvay-epar-medicine-overview_et.pdf)

ελληνικά (EL) (136.23 KB - PDF)

**First published:**

28/07/2021

[View](/el/documents/overview/bylvay-epar-medicine-overview_el.pdf)

français (FR) (114.21 KB - PDF)

**First published:**

28/07/2021

[View](/fr/documents/overview/bylvay-epar-medicine-overview_fr.pdf)

hrvatski (HR) (132.05 KB - PDF)

**First published:**

28/07/2021

[View](/hr/documents/overview/bylvay-epar-medicine-overview_hr.pdf)

italiano (IT) (109.47 KB - PDF)

**First published:**

28/07/2021

[View](/it/documents/overview/bylvay-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (148.3 KB - PDF)

**First published:**

28/07/2021

[View](/lv/documents/overview/bylvay-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (133.54 KB - PDF)

**First published:**

28/07/2021

[View](/lt/documents/overview/bylvay-epar-medicine-overview_lt.pdf)

magyar (HU) (133.51 KB - PDF)

**First published:**

28/07/2021

[View](/hu/documents/overview/bylvay-epar-medicine-overview_hu.pdf)

Malti (MT) (134.7 KB - PDF)

**First published:**

28/07/2021

[View](/mt/documents/overview/bylvay-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.95 KB - PDF)

**First published:**

28/07/2021

[View](/nl/documents/overview/bylvay-epar-medicine-overview_nl.pdf)

polski (PL) (136.57 KB - PDF)

**First published:**

28/07/2021

[View](/pl/documents/overview/bylvay-epar-medicine-overview_pl.pdf)

português (PT) (110.36 KB - PDF)

**First published:**

28/07/2021

[View](/pt/documents/overview/bylvay-epar-medicine-overview_pt.pdf)

română (RO) (131.4 KB - PDF)

**First published:**

28/07/2021

[View](/ro/documents/overview/bylvay-epar-medicine-overview_ro.pdf)

slovenčina (SK) (132.62 KB - PDF)

**First published:**

28/07/2021

[View](/sk/documents/overview/bylvay-epar-medicine-overview_sk.pdf)

slovenščina (SL) (133.6 KB - PDF)

**First published:**

28/07/2021

[View](/sl/documents/overview/bylvay-epar-medicine-overview_sl.pdf)

Suomi (FI) (108.7 KB - PDF)

**First published:**

28/07/2021

[View](/fi/documents/overview/bylvay-epar-medicine-overview_fi.pdf)

svenska (SV) (109 KB - PDF)

**First published:**

28/07/2021

[View](/sv/documents/overview/bylvay-epar-medicine-overview_sv.pdf)

Bylvay : EPAR - Risk management plan

English (EN) (2.96 MB - PDF)

**First published:** 19/05/2025

**Last updated:** 11/07/2025

[View](/en/documents/rmp/bylvay-epar-risk-management-plan_en.pdf)

## Product information

Bylvay : EPAR - Product information

English (EN) (996.25 KB - PDF)

**First published:** 28/07/2021

**Last updated:** 06/06/2025

[View](/en/documents/product-information/bylvay-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-482)

български (BG) (1.14 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/bg/documents/product-information/bylvay-epar-product-information_bg.pdf)

español (ES) (1.04 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/es/documents/product-information/bylvay-epar-product-information_es.pdf)

čeština (CS) (1.09 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/cs/documents/product-information/bylvay-epar-product-information_cs.pdf)

dansk (DA) (1006.91 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/da/documents/product-information/bylvay-epar-product-information_da.pdf)

Deutsch (DE) (1.02 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/de/documents/product-information/bylvay-epar-product-information_de.pdf)

eesti keel (ET) (982.1 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/et/documents/product-information/bylvay-epar-product-information_et.pdf)

ελληνικά (EL) (1.13 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/el/documents/product-information/bylvay-epar-product-information_el.pdf)

français (FR) (1.02 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/fr/documents/product-information/bylvay-epar-product-information_fr.pdf)

hrvatski (HR) (1.11 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/hr/documents/product-information/bylvay-epar-product-information_hr.pdf)

íslenska (IS) (984.86 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/is/documents/product-information/bylvay-epar-product-information_is.pdf)

italiano (IT) (1001.75 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/it/documents/product-information/bylvay-epar-product-information_it.pdf)

latviešu valoda (LV) (1.08 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/lv/documents/product-information/bylvay-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.1 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/lt/documents/product-information/bylvay-epar-product-information_lt.pdf)

magyar (HU) (1.1 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/hu/documents/product-information/bylvay-epar-product-information_hu.pdf)

Malti (MT) (1.12 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/mt/documents/product-information/bylvay-epar-product-information_mt.pdf)

Nederlands (NL) (1021.92 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/nl/documents/product-information/bylvay-epar-product-information_nl.pdf)

norsk (NO) (987.19 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/no/documents/product-information/bylvay-epar-product-information_no.pdf)

polski (PL) (1.12 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/pl/documents/product-information/bylvay-epar-product-information_pl.pdf)

português (PT) (989.16 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/pt/documents/product-information/bylvay-epar-product-information_pt.pdf)

română (RO) (1.1 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/ro/documents/product-information/bylvay-epar-product-information_ro.pdf)

slovenčina (SK) (1.11 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/sk/documents/product-information/bylvay-epar-product-information_sk.pdf)

slovenščina (SL) (1.06 MB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/sl/documents/product-information/bylvay-epar-product-information_sl.pdf)

Suomi (FI) (982.22 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/fi/documents/product-information/bylvay-epar-product-information_fi.pdf)

svenska (SV) (1002.26 KB - PDF)

**First published:**

28/07/2021

**Last updated:**

06/06/2025

[View](/sv/documents/product-information/bylvay-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000274069 06/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Bylvay : EPAR - All authorised presentations

English (EN) (70.52 KB - PDF)

**First published:** 28/07/2021

[View](/en/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-698)

български (BG) (77.29 KB - PDF)

**First published:**

28/07/2021

[View](/bg/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_bg.pdf)

español (ES) (59.37 KB - PDF)

**First published:**

28/07/2021

[View](/es/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_es.pdf)

čeština (CS) (74.91 KB - PDF)

**First published:**

28/07/2021

[View](/cs/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.41 KB - PDF)

**First published:**

28/07/2021

[View](/da/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (61.44 KB - PDF)

**First published:**

28/07/2021

[View](/de/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (60.35 KB - PDF)

**First published:**

28/07/2021

[View](/et/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.87 KB - PDF)

**First published:**

28/07/2021

[View](/el/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_el.pdf)

français (FR) (60.04 KB - PDF)

**First published:**

28/07/2021

[View](/fr/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (76.71 KB - PDF)

**First published:**

28/07/2021

[View](/hr/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (64.93 KB - PDF)

**First published:**

28/07/2021

[View](/is/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.24 KB - PDF)

**First published:**

28/07/2021

[View](/it/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (76.27 KB - PDF)

**First published:**

28/07/2021

[View](/lv/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (78.31 KB - PDF)

**First published:**

28/07/2021

[View](/lt/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (77.51 KB - PDF)

**First published:**

28/07/2021

[View](/hu/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (77.35 KB - PDF)

**First published:**

28/07/2021

[View](/mt/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (60.59 KB - PDF)

**First published:**

28/07/2021

[View](/nl/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (93.48 KB - PDF)

**First published:**

28/07/2021

[View](/no/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_no.pdf)

polski (PL) (78.03 KB - PDF)

**First published:**

28/07/2021

[View](/pl/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.9 KB - PDF)

**First published:**

28/07/2021

[View](/pt/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_pt.pdf)

română (RO) (75.18 KB - PDF)

**First published:**

28/07/2021

[View](/ro/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (76.89 KB - PDF)

**First published:**

28/07/2021

[View](/sk/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (68.71 KB - PDF)

**First published:**

28/07/2021

[View](/sl/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.93 KB - PDF)

**First published:**

28/07/2021

[View](/fi/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.11 KB - PDF)

**First published:**

28/07/2021

[View](/sv/documents/all-authorised-presentations/bylvay-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Bylvay Active substance odevixibat International non-proprietary name (INN) or common name odevixibat Therapeutic area (MeSH) Cholestasis, Intrahepatic Anatomical therapeutic chemical (ATC) code A05AX

### Pharmacotherapeutic group

Bile and liver therapy

### Therapeutic indication

Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4.4 and 5.1).

## Authorisation details

EMA product number EMEA/H/C/004691

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Ipsen Pharma

65 Quai Georges Gorse

Opinion adopted 20/05/2021 Marketing authorisation issued 16/07/2021 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Bylvay : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.28 KB - PDF)

**First published:** 10/04/2025

**Last updated:** 11/07/2025

[View](/en/documents/procedural-steps-after/bylvay-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Bylvay : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (155.31 KB - PDF)

**First published:** 31/05/2022

**Last updated:** 19/05/2025

[View](/en/documents/procedural-steps-after/bylvay-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Bylvay : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMA/CHMP/89429/2025

English (EN) (125.41 KB - PDF)

**First published:** 19/05/2025

[View](/en/documents/pip-compliance/bylvay-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

Bylvay-H-C-004691-II-0022-G : EPAR - Assessment report - Variation

Reference Number: EMA/116534/2025

English (EN) (1.74 MB - PDF)

**First published:** 19/05/2025

[View](/en/documents/variation-report/bylvay-h-c-004691-ii-0022-g-epar-assessment-report-variation_en.pdf)

Bylvay-H-C- PSUSA-00010949-202401: Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/440110/2024

English (EN) (133.57 KB - PDF)

**First published:** 03/04/2025

[View](/en/documents/scientific-conclusion/bylvay-h-c-psusa-00010949-202401-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Bylvay : Orphan maintenance assessment report (post authorisation) (II-11)

Adopted

Reference Number: EMA/OD/0000123138

English (EN) (1.27 MB - PDF)

**First published:** 09/02/2024

[View](/en/documents/orphan-maintenance-report-post/bylvay-orphan-maintenance-assessment-report-post-authorisation-ii-11_en.pdf)

CHMP post-authorisation summary of positive opinion for Bylvay (II-11 )

Adopted

English (EN) (133.51 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bylvay-ii-11_en.pdf)

## Initial marketing authorisation documents

Bylvay : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-685594

English (EN) (519.6 KB - PDF)

**First published:** 28/07/2021

[View](/en/documents/orphan-maintenance-report/bylvay-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Bylvay : EPAR - Public assessment report

Adopted

Reference Number: EMA/319560/2021

English (EN) (3.19 MB - PDF)

**First published:** 28/07/2021

[View](/en/documents/assessment-report/bylvay-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Bylvay

Adopted

Reference Number: EMA/CHMP/273563/2021

English (EN) (143.74 KB - PDF)

**First published:** 21/05/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-bylvay_en.pdf)

#### News on Bylvay

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023) 10/11/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021) 21/05/2021

[First treatment for rare liver disease](/en/news/first-treatment-rare-liver-disease) 21/05/2021

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Bylvay : EPAR - Product information - tracked changes

English (EN) (567.01 KB - DOCX)

**First published:** 19/05/2025

[View](/en/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-732)

български (BG) (533.2 KB - DOCX)

**First published:**

19/05/2025

[View](/bg/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_bg.docx)

español (ES) (558.85 KB - DOCX)

**First published:**

19/05/2025

[View](/es/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_es.docx)

čeština (CS) (536.48 KB - DOCX)

**First published:**

19/05/2025

[View](/cs/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (518.43 KB - DOCX)

**First published:**

19/05/2025

[View](/da/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (537.67 KB - DOCX)

**First published:**

19/05/2025

[View](/de/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (522.13 KB - DOCX)

**First published:**

19/05/2025

[View](/et/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (492.67 KB - DOCX)

**First published:**

19/05/2025

[View](/el/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_el.docx)

français (FR) (526.3 KB - DOCX)

**First published:**

19/05/2025

[View](/fr/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (566.49 KB - DOCX)

**First published:**

19/05/2025

[View](/hr/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (535.76 KB - DOCX)

**First published:**

19/05/2025

[View](/is/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_is.docx)

italiano (IT) (541.96 KB - DOCX)

**First published:**

19/05/2025

[View](/it/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (529.09 KB - DOCX)

**First published:**

19/05/2025

[View](/lv/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (498.77 KB - DOCX)

**First published:**

19/05/2025

[View](/lt/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (521.56 KB - DOCX)

**First published:**

19/05/2025

[View](/hu/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (554.63 KB - DOCX)

**First published:**

19/05/2025

[View](/mt/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (528.51 KB - DOCX)

**First published:**

19/05/2025

[View](/nl/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (597.76 KB - DOCX)

**First published:**

19/05/2025

[View](/no/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_no.docx)

polski (PL) (535.78 KB - DOCX)

**First published:**

19/05/2025

[View](/pl/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_pl.docx)

português (PT) (523.24 KB - DOCX)

**First published:**

19/05/2025

[View](/pt/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_pt.docx)

română (RO) (680.81 KB - DOCX)

**First published:**

19/05/2025

[View](/ro/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (534.87 KB - DOCX)

**First published:**

19/05/2025

[View](/sk/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (525.1 KB - DOCX)

**First published:**

19/05/2025

[View](/sl/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (523.29 KB - DOCX)

**First published:**

19/05/2025

[View](/fi/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (526.58 KB - DOCX)

**First published:**

19/05/2025

[View](/sv/documents/product-information-tracked-changes/bylvay-epar-product-information-tracked-changes_sv.docx)

#### More information on Bylvay

The orphan designation [EU/3/12/1040](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1040) was withdrawn from the Union Register of orphan medicinal products by the European Commission in November 2023.

#### More information on Bylvay

- [EU/3/12/1028 - orphan designation for treatment of progressive familial intrahepatic cholestasis](/en/medicines/human/orphan-designations/eu-3-12-1028)
- [EMEA-002054-PIP01-16-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002054-pip01-16-m03)
- [Bylvay - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/bylvay-0)
- [Prospective Registry-Based Study of the Long-Term Safety of Odevixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - post-authorisation study](https://catalogues.ema.europa.eu/study/106458)
- [Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000441)

**This page was last updated on** 11/07/2025

## Share this page

[Back to top](#main-content)